Nicolas Dulphy
Overview
Explore the profile of Nicolas Dulphy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bentivegna S, Almosailleakh M, Zhao L, Schuster M, Benquet S, Balhuizen A, et al.
Exp Hematol Oncol
. 2025 Jan;
14(1):10.
PMID: 39885602
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood or bone marrow cells carry mutations associated with hematological malignancies. Individuals with CHIP have an increased risk of developing...
2.
Wlosik J, Orlanducci F, Richaud M, Demerle C, Ben Amara A, Rouviere M, et al.
Front Immunol
. 2025 Jan;
15:1487792.
PMID: 39867888
Introduction: Acute myeloid leukemia (AML) is a rare haematological cancer with poor 5-years overall survival (OS) and high relapse rate. Leukemic cells are sensitive to Natural Killer (NK) cell mediated...
3.
Rondeau V, Kalogeraki M, Roland L, Nader Z, Gourhand V, Bonaud A, et al.
Sci Signal
. 2024 Oct;
17(860):eadl5100.
PMID: 39471249
Both cell-intrinsic and niche-derived, cell-extrinsic cues drive the specification of hematopoietic multipotent progenitors (MPPs) in the bone marrow, which comprise multipotent MPP1 cells and lineage-restricted MPP2, MPP3, and MPP4 subsets....
4.
Ganesan S, Awan-Toor S, Guidez F, Maslah N, Rahimy R, Aoun C, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39470742
Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the...
5.
Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K, et al.
Hemasphere
. 2024 May;
8(5):e64.
PMID: 38756352
Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models...
6.
Fandrei D, Huynh T, Sebert M, Aguinaga L, Bisio V, Kim R, et al.
Blood Cancer J
. 2023 Dec;
13(1):193.
PMID: 38123548
No abstract available.
7.
Adib Y, Boy M, Serror K, Dulphy N, Courtils C, Duciel L, et al.
Front Immunol
. 2023 Apr;
14:1141047.
PMID: 37090742
Natural Killer (NK) cells participate in the defense against infection by killing pathogens and infected cells and secreting immuno-modulatory cytokines. Defects in NK cell activity have been reported in obese,...
8.
Anginot A, Nguyen J, Nader Z, Rondeau V, Bonaud A, Kalogeraki M, et al.
Nat Commun
. 2023 Apr;
14(1):2058.
PMID: 37045841
WHIM Syndrome is a rare immunodeficiency caused by gain-of-function CXCR4 mutations. Here we report a decrease in bone mineral density in 25% of WHIM patients and bone defects leading to...
9.
Zhao L, Sebert M, Mekinian A, Fain O, Espeli M, Balabanian K, et al.
Leukemia
. 2023 Apr;
37(6):1186-1190.
PMID: 37024519
No abstract available.
10.
Boy M, Bisio V, Zhao L, Guidez F, Schell B, Lereclus E, et al.
Nat Commun
. 2023 Feb;
14(1):588.
PMID: 36737440
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders, representing high risk of progression to acute myeloid leukaemia, and frequently associated to somatic mutations, notably in the epigenetic regulator TET2. Natural Killer...